Congestive Heart Failure (Compensated, Investigational Adjunct)
Investigational adjunct in compensated NYHA II heart failure; no RCT support; guideline-directed medical therapy remains primary.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for heart failure. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for CHF is highly investigational.
- Welche Evidenz existiert?
- Tier C (highly investigational). Only anecdotal case series report subjective symptom improvement; there are no randomized controlled trials and no mortality or hospitalization data. Evidence-based therapy per ACC/AHA/HFSA 2022 guidelines (Guideline-Directed Medical Therapy) includes ARNI (sacubitril/valsartan) or ACE inhibitor / ARB, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — these reduce all-cause mortality and hospitalization. Many HF patients require anticoagulation or antiplatelet therapy, which contraindicate leech application.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening anemia in patients with cumulative blood loss across sessions
- Hypotension or orthostasis, especially on aggressive diuretic regimens
- Light-headedness, fainting, or fall risk
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Delay or replacement of GDMT with risk of decompensation, hospitalization, or death
- Wer dies nicht in Betracht ziehen sollte
- Patients with NYHA III or IV decompensated heart failure
- Patients on any anticoagulant or dual antiplatelet therapy
- Patients within 3 months of MI, unstable angina, or revascularization
- Patients with symptomatic orthostatic hypotension or recurrent falls
- Patients with severe valvular disease awaiting surgical intervention
- Patients with severe anemia (Hb under 10 g/dL), active infection, or immunosuppression
- Pregnant patients
- Was Sie Ihren Kliniker fragen sollten
- Am I on full guideline-directed medical therapy (ARNI / ACE-ARB, beta-blocker, MRA, SGLT2 inhibitor)?
- What is my left-ventricular ejection fraction, NYHA class, and BNP / NT-proBNP trend?
- Am I a candidate for additional therapies (CRT, ICD, mitral valve repair, transplant, LVAD)?
- What is my cardiology team's opinion on complementary therapy in my specific case?
- Will my anticoagulant / antiplatelet status be reviewed before any leech application?
- What is the practitioner's experience and Aeromonas-prevention plan?
- How will diuretic dosing and weights be monitored during treatment?
- Wann dringende medizinische Versorgung suchen
- Shortness of breath at rest, inability to lie flat, or new orthopnea
- Weight gain over 2 kg / 4 lbs in 2 days, new or worsening leg swelling
- Chest pain, pressure, or palpitations (call 911 if severe)
- Light-headedness, fainting, or a fall
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F, spreading redness, or pus
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for heart failure.
- Anecdotal series do NOT establish efficacy on hospitalization or mortality.
- Mechanism rationale (preload reduction) does NOT establish clinical benefit equivalent to proven therapies.
- Leech therapy is NEVER a substitute for full GDMT or device therapy when indicated.
- Anticoagulation or antiplatelet therapy should NOT be paused for complementary therapy.
Sicherheits-Querverweise
Clinical Profile
- Category
- cardiovascular
- ICD-10
- I50.22, I50.32, I50.42, I50.9
- Safety tier
- high
Evidence Summary
Heart failure management is dictated by ACC/AHA/HFSA guideline-directed medical therapy (ARNI, beta-blocker, MRA, SGLT2 inhibitor). No PubMed-indexed clinical trial or case series of hirudotherapy for congestive heart failure has been published; use for this indication is investigational and mechanistic only. Critical concerns: many HF patients take anticoagulants (for comorbid atrial fibrillation) or antiplatelets (post-MI), which contraindicate leech application, and aggressive diuresis with orthostasis raises bleeding-tolerance concerns.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Sotnikov OS et al. (2010)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Anticoagulant or dual antiplatelet therapy
- NYHA III-IV decompensated heart failure
- Recent MI or unstable angina (<3 months)
- Symptomatic orthostatic hypotension
- Severe valvular disease awaiting surgery
Related Conditions
Essential Hypertension (Adjunctive)
Investigational adjunctive use; mechanism includes mild diuresis from blood-volume removal and hirudin-mediated vascular endothelial effects. Not a substitute for pharmacotherapy.
Atrial Fibrillation (Adjunctive Investigational)
Highly investigational adjunct for paroxysmal atrial fibrillation; no controlled trials; conventional anticoagulation and rate/rhythm control remain primary.
Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.